CA
NZ
UK
AU
IND
US
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced a second-quarter earnings per share (EPS) of $4.27 on August 4, 2026, marking an 18% increase compared to the previous year. This figure exceeded the consensus estimate of $4.02, highlighting the company’s ability to outperform market expectations amidst …
ImmunityBio, Inc. (NASDAQ: IBRX) announced a record net product revenue of $50.7 million for Q2 2026, a strong 92% increase year-over-year. The growth marks the eighth consecutive quarter of sequential revenue advancement since the commercial launch of its immunotherapy product, ANKTIVA. The company's positive …
Investors now have a clearer view of the company’s ability to generate cash amid a diversified health‑care services platform.
Integer Holdings Corp. (NYSE: ITGR) is set to undergo a transformative merger, allowing shareholders to receive $127 per share in cash. This valuation comes as part of an Agreement and Plan of Merger finalized on August 2, 2026. This agreement positions Integer as a …
Johnson & Johnson (NYSE: JNJ) has announced the appointment of Tom Cavanaugh as Executive Vice President and Worldwide Chairman of Innovative Medicine, effective September 1, 2026. This leadership transition follows the retirement of Jennifer Taubert, who concluded a distinguished 21-year tenure, during which the …
The digital musculoskeletal care provider also raised its full-year 2026 revenue guidance to an $858 million midpoint, reflecting anticipated 46% growth, and announced the strategic acquisition of Cylinder Health for $105 million in cash. These actions underscore the company's strong financial health and its …
Humana’s shares fell 2.5% to $365.00, highlighting concerns despite a 38.4% increase year-to-date. The company’s performance is critical for investors as it strives to regain momentum within a competitive healthcare market.Key HighlightsHumana Inc. (HUM) shares experienced a 2.5% decline on August 3, settling at …
IBio, Inc. has appointed Dr. Molly Carr as its new Chief Medical Officer, effective July 31, 2026. Carr joins iBio with a strong background in the biotechnology sector, having most recently served as Clinical Head at Eli Lilly. This leadership transition comes as the …
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) reported a second-quarter loss of $-1.11 per share, missing analyst expectations of $-1.01 for the quarter ending June 30, 2026. This compares with the $-1.17 loss reported in the prior quarter. The underwhelming performance could raise concerns among investors, …
This 18% year-over-year increase illustrates the company's ongoing strength in pet healthcare innovation. With total revenues reaching $1,217 million, representing a 10% increase, the results reflect successful execution of its growth strategies in a competitive environment. Sector peers like ABT, ISRG, and SYK are …
Please wait processing your request...